<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5766">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097304</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-00450</org_study_id>
    <secondary_id>NCI-2012-00450</secondary_id>
    <secondary_id>CDR0000669111</secondary_id>
    <secondary_id>09-0141-03</secondary_id>
    <secondary_id>UAZ08-11-01</secondary_id>
    <secondary_id>P50CA095060</secondary_id>
    <secondary_id>N01CN35158</secondary_id>
    <secondary_id>P30CA023074</secondary_id>
    <nct_id>NCT01097304</nct_id>
  </id_info>
  <brief_title>Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia</brief_title>
  <official_title>Clinical Study of Ursodeoxycholic Acid in Barrett's Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase II trial studies how well ursodiol works in treating patients with Barrett
      esophagus or cells that look abnormal under a microscope but are not cancer (low-grade
      dysplasia). Chemoprevention is the use of certain drugs to keep cancer from forming. The use
      of ursodiol may keep cancer for forming in patients with Barrett esophagus or low-grade
      dysplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the ability of UDCA (ursodiol) treatment to reverse oxidative
      deoxyribonucleic acid (DNA) damage in the esophageal epithelium of subjects with Barrett's
      esophagus.

      SECONDARY OBJECTIVES:

      I. To determine the effects of UDCA treatment on gastric bile acid composition and on cell
      proliferation in Barrett's epithelium.

      OUTLINE:

      Patients receive ursodiol orally (PO) twice daily (BID) for 6 months in the absence of
      disease progression or unacceptable toxicity.

      After completion of study therapy, patients are followed up for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>8OHdG will be assessed by percentage of positively stained nuclear area. A paired t-test at a one-sided 0.05 significance level will be used to assess change during intervention. The observed results will be reported along with the corresponding confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Gastric Bile Acid Composition, Measured by Liquid Chromatography-tandem Mass Spectrometry, From Baseline to Post-intervention</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Results will be analyzed using paired t-tests. Results (mean values and changes during intervention) will be reported along with the corresponding confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cell Proliferation in BE Epithelium From Baseline to Post-intervention as Assessed by Proliferation-related Ki-67 Antigen (Ki67) Immunostaining, Percentage of Positively Stained Nuclei, in BE Tissue Sections</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Results will be analyzed using paired t-tests. Results (mean values and changes during intervention) will be reported along with the corresponding confidence intervals.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Barrett Esophagus</condition>
  <condition>Esophageal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (ursodiol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodiol</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (ursodiol)</arm_group_label>
    <other_name>Actigall</other_name>
    <other_name>Deursil</other_name>
    <other_name>UDCA</other_name>
    <other_name>URSO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ursodiol)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Barrett's esophagus with histologically-confirmed intestinal metaplasia
             anywhere in the tubular esophagus either with &gt;= 2 cm of involvement or with a
             minimum circumferential Barrett's esophagus (BE) length of 1 cm

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Leukocytes &gt;= 3,000/uL

          -  Absolute neutrophil count &gt;= 1,500/uL

          -  Platelets &gt;= 100,000/uL

          -  Total bilirubin =&lt; 2.0 mg/dL

          -  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2 X institutional upper limit of normal (ULN)

          -  Creatinine =&lt; 1X ULN

          -  Women of child-bearing potential (i.e., not surgically sterile or less than one year
             since last menstrual period) agree to use adequate contraception (hormonal or barrier
             method of birth control; abstinence) prior to study entry and for the duration of
             study participation; women of childbearing potential must have a negative urine
             pregnancy test within 14 days prior to study agent administration; male subjects must
             agree to use adequate contraception (barrier method, abstinence, subject has had
             vasectomy or partner is using effective birth control or is postmenopausal)

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Agree to refrain from any non-steroidal anti-inflammatory drug (NSAID) with the
             exception of low-dose aspirin (81 mg once daily [QD]) during the entire study period

          -  Agree not to take aluminum-containing antacids and anion exchange resins such as
             cholestyramine, colestimide or colestipol within 2 hours of taking UDCA

        Exclusion Criteria:

          -  Barrett's esophagus with high grade dysplasia or carcinoma at enrollment

          -  Medical conditions which would make completing endoscopies or completing the trial
             difficult including but not limited to previous transient ischemic attacks or
             cerebral vascular disease, severe respiratory disease, severe ischemic heart disease
             or myocardial infarction in the previous 6 months, inflammatory bowel disease

          -  Participants may not be receiving any other investigational agents within 1 month of
             study enrollment

          -  Have used NSAID for more than 5 days per month within 1 month of enrollment except
             low dose aspirin (81 mg QD)

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to UDCA

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant and breastfeeding women are excluded from this study; breastfeeding should
             be discontinued during treatment; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her study physician
             immediately

          -  Have had major upper gastrointestinal (GI) surgeries within 6 months of enrollment
             including, but not limited to, fundoplication, bariatric surgery, cholecystectomy

          -  Erosive esophagitis detected at the baseline endoscopy

          -  Participants who need concurrent chemotherapy, radiotherapy, or cancer-related
             hormonal or immunotherapy during the time of study

          -  Participants who have had chemotherapy, radiotherapy, or cancer-related hormonal or
             immunotherapy within 18 months of the baseline visit

          -  Current or planned use of anticoagulant drugs including, but not limited to,
             warfarin, heparin, low molecular weight heparin, Plavix, or Aggrenox

          -  Use of cyclosporine during the time of study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhaskar Banerjee</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Arizona Veterans Affairs Health Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center-North Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>April 29, 2015</lastchanged_date>
  <firstreceived_date>March 31, 2010</firstreceived_date>
  <firstreceived_results_date>April 29, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Ursodiol)</title>
          <description>Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
Ursodiol: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Ursodiol)</title>
          <description>Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
Ursodiol: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="62.8" spread="10.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining</title>
        <description>8OHdG will be assessed by percentage of positively stained nuclear area. A paired t-test at a one-sided 0.05 significance level will be used to assess change during intervention. The observed results will be reported along with the corresponding confidence intervals.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>participants with fewer than 500 total nuclei in longitudinally sectioned crypts opening to the lumen were excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Ursodiol)</title>
            <description>Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
Ursodiol: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining</title>
            <description>8OHdG will be assessed by percentage of positively stained nuclear area. A paired t-test at a one-sided 0.05 significance level will be used to assess change during intervention. The observed results will be reported along with the corresponding confidence intervals.</description>
            <units>% of strongly/moderately stained nuclei</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.62" spread="13.13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Gastric Bile Acid Composition, Measured by Liquid Chromatography-tandem Mass Spectrometry, From Baseline to Post-intervention</title>
        <description>Results will be analyzed using paired t-tests. Results (mean values and changes during intervention) will be reported along with the corresponding confidence intervals.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Cell Proliferation in BE Epithelium From Baseline to Post-intervention as Assessed by Proliferation-related Ki-67 Antigen (Ki67) Immunostaining, Percentage of Positively Stained Nuclei, in BE Tissue Sections</title>
        <description>Results will be analyzed using paired t-tests. Results (mean values and changes during intervention) will be reported along with the corresponding confidence intervals.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Ursodiol)</title>
          <description>Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
Ursodiol: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ischemia/Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Chest/Thorax pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Barrett's esophagus with at least intramucosal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Post surgical pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Distention/Bloating</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Phytobezoar</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdomen pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper airway infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sherry Chow</name_or_title>
      <organization>University of Arizona</organization>
      <phone>520-626-3358</phone>
      <email>schow@azcc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
